Clinical Trials Logo

Esophageal and Gastric Varices clinical trials

View clinical trials related to Esophageal and Gastric Varices.

Filter by:

NCT ID: NCT06370169 Recruiting - Clinical trials for Gastric Varices Bleeding

EUS Guided Coil Embolization for Primary Prophylaxis of Gastric Varices

EUS
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The standard treatment of bleeding gastric varices is obliteration with placement of coil and glue. Our study will evaluate the efficacy of EUS guided coil as primary prophylaxis for high-risk gastric varices. All procedures will be performed with patient under deep sedation or general anaesthesia under the supervision of an anaesthesiologist.

NCT ID: NCT06214234 Not yet recruiting - Esophageal Varices Clinical Trials

Upper Endoscopy in Cirrhotic Patients With Upper Gastrointestinal Bleeding

Varices
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

Liver cirrhosis is a common diffuse and persistent liver disease often accompanied by portal hypertension, liver failure, upper gastrointestinal bleeding (UGIB), and other complications. The incidence rate of liver cirrhosis with UGIB is as high as 30-40%, which is related to the rupture bleeding of gastroesophageal varices (GOV), hepatogenic ulcer, portal hypertensive gastropathy, hepatic gastrointestinal failure, etc

NCT ID: NCT06122792 Not yet recruiting - Portal Hypertension Clinical Trials

Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis

Start date: January 2024
Phase: N/A
Study type: Interventional

The prevalence of gastric varices is approximately 20%. It is important to note that gastric varices tend to bleed more severely, have a higher morbidity and mortality rate, and have a 35% to 90% risk of rebleeding after the cessation of acute hemorrhage. Because of the relatively low prevalence of gastric varices, the existing clinical studies have many deficiencies, and there is much controversy in the academic community, the optimal treatment and prevention strategies for gastric varices have not yet been fully defined. In the last few years, important advances have been made in the treatment and prevention of gastric variceal bleeding in patients with cirrhosis. Experts agree that the combination of pharmacological and endoscopic injection of tissue adhesives should be the first line of therapy in the acute bleeding episode from isolated gastric varices (IGV1) or type 2 gastroesophageal varices (GOV2) varices; whereas transjugular intrahepatic portosystemic shunt (TIPS) is considered a rescue therapy. TIPS has been shown to effectively prevent variceal rebleeding but with a potential increase in the incidence of hepatic encephalopathy and/or liver failure. In this sense, a recent randomized controlled trial (RCT) in fundal variceal bleeding showed that an early TIPS, performed during the first 5 days after patient admission resulted in a significant decrease in failure to control bleeding and early and late rebleeding. However, the study was conducted for 4 years and only included 25 patients. Due to insufficient sample size, it was unable to reflect whether priority TIPS can bring survival benefits to patients with gastric variceal bleeding. Therefore, there is an urgent need for multi-center clinical studies with large samples to provide high-quality evidence in the field of prioritizing TIPS for the treatment of acute gastric variceal bleeding. The present study aims to compare the preemptive TIPS (performed during the first 72 hours after endoscopy) with standard second prophylaxis (endoscopic injection of tissue adhesives plus carvedilol) for patients with acute bleeding from gastric varices (IGV1 or GOV2). The primary outcome will be a 6-week mortality from inclusion.

NCT ID: NCT06122753 Not yet recruiting - Portal Hypertension Clinical Trials

Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis

Start date: January 2024
Phase: N/A
Study type: Interventional

Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive TIPS is still controversial. The present study is directed at comparing the outcome of patients with acute variceal bleeding with occlusive PVT treated by standard therapy (vasoactive drugs + endoscopic variceal ligation) with or without preemptive TIPS (performed during the first 1-3 days after endoscopic procedure). The primary outcome is survival free of variceal rebleeding at 6 weeks from inclusion.

NCT ID: NCT06106971 Recruiting - Clinical trials for Gastric Varices Bleeding

Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding

Start date: June 28, 2018
Phase: Phase 3
Study type: Interventional

The goal of this randomized controlled trial is to compare the rebleeding rate in cirhotic patients with gastric variceal bleeding receiving balloon-occluded retrograde transvenous obliteration and endoscopic tissue glue injection. The main questions it aims to answer are: - Recurrent gastric variceal bleeding - Further decompensation of liver cirrhosis Participants will receive balloon-occluded retrograde transvenous obliteration and endoscopic tissue glue injection. Researchers will compare balloon-occluded retrograde transvenous obliteration and endoscopic tissue glue injection to see if the rebleeding rate associated with balloon-occluded retrograde transvenous obliteration is lower than that associated with endoscopic tissue glue injection.

NCT ID: NCT06082219 Not yet recruiting - Esophageal Varices Clinical Trials

Ulcer Bleeding After Band Ligation of Esophageal Varices

Start date: January 1, 2024
Phase:
Study type: Observational

Primary Outcomes: assessment of incidence , risk factors and prognosis of post-banding ulcer bleeding following EVL in patients with liver cirrhosis. Secondary Outcomes: minimize post-banding ulcer bleeding

NCT ID: NCT06050837 Not yet recruiting - Clinical trials for High Risk Esophageal Varices

Spleen Stiffness as a Measure to Assess the REsponse to β Blocker Therapy (SPARE-B)

Start date: September 30, 2023
Phase:
Study type: Observational

HVPG is the gold standard for measurement of the presence and severity of portal hypertension. Clinically Significant Portal Hypertension (CSPH) is defined as HVPG ≥ 10 mmHg. Reducing the HVPG by use of non-selective beta blockers has been associated with reduced risk of variceal hemorrhage, ascites, SBP and thus has a positive effect on survival. Response to Beta blocker therapy is defined as a reduction of HVPG by 10% or to ≤ 12 mmHg. HVPG is an invasive method of assessment of portal pressures, with lack of availability at many centres. While non-invasive tests to predict CSPH have been defined, predicting response to beta-blockers non-invasively is an unmet clinical need. The aim of this study is to use splenic stiffness measurement, a non-invasive test, as a surrogate to assess the response of HVPG to beta blocker therapy.

NCT ID: NCT06017102 Recruiting - Esophageal Varices Clinical Trials

Wired Magnetically Assisted Capsule Endoscopy and Esophageal Varices

Start date: September 5, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the safeness and effectiveness of traditional esophagogastroduodenoscope (EGD) and wired magnetically assisted capsule endoscopy (MACE) in the diagnosis of esophageal varices in biliary atresia (BA) patients. The main questions it aims to answer are: - Subjects who do wired magnetically assisted capsule endoscopy do not need to open the mouths during the process, this study also want to know whether wired magnetically assisted capsule endoscopy can reduce the generation of droplets. - Diagnostic accuracy between traditional esophagogastroduodenoscope and wired magnetically assisted capsule endoscopy in biliary atresia patients with esophageal varices. Participants will do either traditional esophagogastroduodenoscope or wired magnetically assisted capsule endoscopy.

NCT ID: NCT05979935 Active, not recruiting - Clinical trials for Esophageal and Gastric Varices

Prediction of Esophageal Varices in Liver Cirrhosis Using Tongue Bioinformatics

Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to compare the tongue bioinformatics of high-risk and low-risk patients with esophageal varices due to liver cirrhosis. The main question of this study is to explore whether there exists a relationship between the degree of esophageal varices and tongue bioinformatics in liver cirrhosis. it aims to answer 2 questions as below: question 1: If these is a significant difference in tongue bioinformatics between patients in liver cirrhosis with high-risk and low-risk of esophageal varices. Question 2; If tongue bioinformatics can be used as a diagnostic basic for testing esophageal varices in liver cirrhosis. Firstly, participants will be divided into two groups according to their degree of esophageal varices from electronic gastroscopy report and CT scan report including high-risk group and low-risk group. Secondly, participants will be asked to show their tongue, including the surface and sublingual veins of tongue, and the tongue images of each participants will be collected by researchers via camera. After finishing tongue image collection, participants will receive a professional tongue diagnosis report in Traditional Chinese Medicine and health suggestion.

NCT ID: NCT05978752 Not yet recruiting - Clinical trials for Esophageal and Gastric Varices

Clinical Study on Endoscopic Management of GOV1 Esophagogastric Varices

Start date: December 2023
Phase: N/A
Study type: Interventional

The patients with GOV1 esophagogastric varices will be treated with gastric variceal tissue gel injection, at the same time, the esophageal varices were treated with ligation, sclerotherapy, or no treatment. A new method for the treatment of esophageal varices will be proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding HVPG testing to develop the best strategy for secondary prevention of endoscopic treatment in patients with GOV1 type esophageal and gastric varices.